Liver fat content, insulin absorption and action sis determinants of insulin requirements in type 2 diabetes

被引：0
|
作者：
Ryysy, L
Hakkinen, AM
Halavaara, J
Yki-Jarvinen, H
机构：
来源：
DIABETES | 1999年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0413
引用
收藏
页码：A96 / A96
页数：1
相关论文
共 50 条
  • [1] Liver fat content, insulin absorption and action as determinants of insulin requirements in type 2 diabetes.
    Ryysy, L
    Häkkinen, AM
    Goto, T
    Vehkavaara, S
    Westerbacka, J
    Halavaara, J
    Yki-Järvinen, H
    DIABETOLOGIA, 1999, 42 : A83 - A83
  • [2] Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
    Juurinen, L
    Tiikkainen, M
    Häkkinen, AM
    Järvinen, H
    DIABETOLOGIA, 2005, 48 : A59 - A59
  • [3] Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
    Juurinen, Leena
    Tiikkainen, Mirja
    Hakkinen, Anna-Maija
    Hakkarainen, Antti
    Yki-Jarvinen, Hannele
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 292 (03): : E829 - E835
  • [4] Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients
    Ryysy, L
    Häkkinen, AM
    Goto, T
    Vehkavaara, S
    Westerbacka, J
    Halavaara, J
    Yki-Järvinen, H
    DIABETES, 2000, 49 (05) : 749 - 758
  • [5] Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
    Cusi, K.
    Sanyal, A. J.
    Zhang, S.
    Hoogwerf, B. J.
    Chang, A. M.
    Jacober, S. J.
    Bue-Valleskey, J. M.
    Higdon, A. N.
    Bastyr, E. J., III
    Haupt, A.
    Hartman, M. L.
    DIABETES OBESITY & METABOLISM, 2016, 18 : 50 - 58
  • [6] Insulin signaling and action in fat cells: Associations with insulin resistance and type 2 diabetes
    Smith, U
    Axelsen, M
    Carvalho, E
    Eliasson, B
    Jansson, PA
    Wesslau, C
    THE METABOLIC SYNDROME X: CONVERGENCE OF INSULIN RESISTANCE, GLUCOSE INTOLERANCE, HYPERTENSION, OBESITY, AND DYSLIPIDEMIAS-SEARCHING FOR THE UNDERLYING DEFECTS, 1999, 892 : 119 - 126
  • [7] Liver Fat in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
    Yki-Jarvinen, Hannele
    DIGESTIVE DISEASES, 2010, 28 (01) : 203 - 209
  • [8] Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses
    Juurinen, Leena
    Kotronen, Anna
    Graner, Marit
    Yki-Jarvinen, Hannele
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (01): : 118 - 124
  • [9] Liver Fat Content and Hepatic Insulin Sensitivity in Overweight Patients With Type 1 Diabetes
    Llaurado, Gemma
    Sevastianova, Ksenia
    Sadevirta, Sanja
    Hakkarainen, Antti
    Lundbom, Nina
    Orho-Melander, Marju
    Groop, Per-Henrik
    Forsblom, Carol
    Yki-Jarvinen, Hannele
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02): : 607 - 616
  • [10] Effects of addition of rosiglitatzone to combination therapy with insulin and metformin on liver fat, insulin sensitivity, glycemic control and insulin requirements in patients with Type 2 diabetes requiring high doses of insulin
    Juurinen, L
    Tiikkainen, M
    Graner, M
    Häkkinen, AM
    Yki-Järvinen, H
    DIABETOLOGIA, 2004, 47 : A258 - A258
12345